GlassScriptPhysician profile
Maia Vandyke
NPI 1265966717
$79,388.05
in general payments reported to CMS, 2019-2025
14 companies · $16K in 2025
The $16K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $54K · 2023: $4,227 · 2024: $5,524 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $5,494 · Travel and Lodging: $4,637 · Consulting Fee: $2,250 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,825.00 |
| Food and Beverage | $5,493.83 |
| Travel and Lodging | $4,637.17 |
| Consulting Fee | $2,250.00 |
| Education | $315.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $75,950.94 | 2021-2025 | Advance Xp, Ams 700, Ams 700 Cxr Rte Kit |
| Laborie Medical Technologies Corp. | $1,820.31 | 2022-2025 | Optilume Urethral Drug Coated Balloon, Optilume Bph Drug Coated Balloon Catheter |
| Coloplast Corp | $685.54 | 2022-2025 | Titan |
| Medtronic, INC. | $414.89 | 2021-2024 | Interstim |
| Convatec INC. | $137.41 | 2023-2024 | |
| Antares Pharma, INC. | $90.51 | 2024-2025 | Xyosted |
| Urogen Pharma, INC. | $58.29 | 2023-2024 | Jelmyto |
| Innovation Technologies INC | $49.32 | 2024 | Irrisept |
| Tolmar, INC. | $41.08 | 2023-2025 | Eligard, Jatenzo |
| Aveo Pharmaceuticals, INC. | $36.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Olympus America INC. | $28.66 | 2024 | Itind System |
| Ferring Pharmaceuticals INC. | $20.20 | 2024 | Adstiladrin |
| Merck Sharp & Dohme LLC | $19.47 | 2023 | Lynparza, Welireg, Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maia Vandyke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.